Abstract: Aqueous formulations and kits of radiopharmaceutical compounds of general Formula (II) protected from radiolysis with stabilisers, such as L-methionine and gentisic acid, are disclosed, wherein the compounds are based on sarcophagine ligands coordinated to a radioisotope, such as 64-copper, and linked to a tetrazine group for reaction with tumour targeting antibodies having functional reactive groups such as trans-cyclooctene, processes of preparing said radioligand formulations, and uses thereof for radioimaging, diagnosing and treating cancer.
Abstract: The present invention relates to formulations of radiolabeled compounds that are of use in radiotherapy and diagnostic imaging related to prostate specific membrane antigen (PSMA).
Type:
Application
Filed:
May 22, 2020
Publication date:
October 6, 2022
Applicant:
Clarity Pharmaceuticals Limited
Inventors:
Paul Stephen DONNELLY, Nicholas Alan ZIA, Lawson Kyle SPARE, Ellen Marianne VAN DAM, Kevin Kar Weng KUAN